Markets:

Overview

News

Currencies

International

Treasuries

Bright Minds Biosciences Inc. - common stock (NQ:DRUG)

75.97 +3.97 (+5.51%)

Streaming Delayed Price Updated: 12:42 PM EDT, Mar 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Bright Minds Biosciences Inc. - common stock

< Previous 1 2 3 4 5 Next >

The market is filled with gapping stocks in Wednesday's session. ↗

January 07, 2026

Via Chartmill

Traders are paying attention to the gapping stocks in Tuesday's session. ↗

January 06, 2026

Via Chartmill

Why Did DRUG Stock Rocket 51% Today? ↗

January 06, 2026

The Phase 2 BREAKTHROUGH trial met its primary goals, showing strong reductions in seizure frequency while maintaining a favorable safety profile.

Via Stocktwits

Stay updated with the stocks that are on the move in today's pre-market session. ↗

January 06, 2026

Via Chartmill

Why Bright Minds Biosciences Stock Topped the Market on Monday ↗

November 17, 2025

The company isn't wasting any time drafting seasoned professionals to help it develop medication for a rare genetic disorder.

Via The Motley Fool

Large Patient Population Is Key Driver For Bright Minds' Growth ↗

September 08, 2025

BTIG initiates coverage on Bright Minds Biosciences with a Buy rating, citing BMB‑101's potential and key Phase 2 data expected by the end of 2025

Via Benzinga

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside ↗

May 07, 2025

Chardan initiates Bright Minds with a Buy rating, citing over $1 billion sales potential for epilepsy drug BMB-101 despite limited clinical data.

Via Benzinga

Biotechs on the Brink: 2 Stocks With Huge Potential

February 14, 2025

BriaCell Therapeutics and Recursion Pharmaceuticals are two biotech firms that may be poised for success in 2025; risk-tolerant investors might keep an eye out.

Via MarketBeat

This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday ↗

January 23, 2025

Via Benzinga

Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month ↗

November 13, 2024

The reason for the stock's rapid ascent is a mystery.

Via The Motley Fool

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank? ↗

November 04, 2024

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

Via Benzinga

Topics Government

What's Going On With Bright Minds Biosciences Stock? ↗

October 21, 2024

Bright Minds Biosciences Inc (NASDAQ:DRUG) shares are trading higher again after soaring last week. The company on Monday announced a new collaboration with brain health-focused AI company Firefly...

Via Benzinga

Topics Artificial Intelligence

Crude Oil Down Over 1%; American Express Shares Fall After Q3 Results ↗

October 18, 2024

Via Benzinga

What's Going On With Bright Minds Biosciences Stock Friday? ↗

October 18, 2024

Bright Minds Biosciences shares are moving higher on Friday. The company announced a $35 million non-brokered private placement.

Via Benzinga

Dow Falls Over 100 Points; Netflix Posts Upbeat Results ↗

October 18, 2024

Via Benzinga

Topics Stocks

Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis ↗

October 17, 2024

Firefly Neuroscience partners with Bright Minds Biosciences to analyze positive Phase 1 data of BMB-101 using advanced AI technology, setting the stage for Phase 2 trials.

Via Benzinga

Topics Artificial Intelligence

Dow Jumps 250 Points; U.S. Bancorp Earnings Top Views ↗

October 16, 2024

Via Benzinga

Topics Stocks

US Stocks Mixed; Abbott Reports Better-Than-Expected Q3 Results ↗

October 16, 2024

Via Benzinga

Why Ericsson Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

October 15, 2024

Via Benzinga

Bright Minds Biosciences Reports Improved Financial Position For Q3 Amid Ongoing R&D Efforts ↗

August 16, 2024

Bright Minds Biosciences reports a significant reduction in net losses for Q3 2024 while advancing its R&D programs focused on serotonergic therapies for CNS disorders.

Via Benzinga

DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024 ↗

August 15, 2024

Bright Minds Biosciences just reported results for the third quarter of 2024.

Via InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

August 12, 2024

It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!

Via InvestorPlace

DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024 ↗

May 20, 2024

Bright Minds Biosciences just reported results for the second quarter of 2024.

Via InvestorPlace

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More ↗

February 15, 2024

Via Benzinga

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.